Exagen Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 183
Employees
  • Stock Symbol
  • XGN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $8.39
  • (As of Thursday Closing)

Exagen General Information

Description

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.

Contact Information

Website
www.exagen.com
Formerly Known As
Exagen Diagnostics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1261 Liberty Way
  • Suite C
  • Vista, CA 92081
  • United States
+1 (888) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Exagen Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.39 $8.63 $8.35 - $24.67 $139M 16.2M 37.5K -$1.54

Exagen Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 134,368 132,299 267,077
Revenue 48,278 41,975 40,387 32,440
EBITDA (19,764) (13,655) (7,931) (4,355)
Net Income (23,251) (16,687) (12,038) (8,012)
Total Assets 127,772 78,375 88,310 28,887
Total Debt 27,874 26,967 26,092 24,698
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Exagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis a
Laboratory Services (Healthcare)
Vista, CA
183 As of 2020
00000
0000 0000-00-00
00000000 00000

00000000

a commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000 000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000

00000 00

d minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
0000000000000
Aliso Viejo, CA
000 As of 0000
00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exagen Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Veracyte Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000 00000000 Private Equity-Backed Aliso Viejo, CA 000 000000&0
0000000 0000 Venture Capital-Backed Sunnyvale, CA 00 0000 00000000000 0000
00000000 Formerly VC-backed Boulder, CO 000 00000 000000000 00000
0000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 31 competitors. Get the full list »

Exagen Patents

Exagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210220389-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019 0000000000
JP-6453299-B2 Methods for treating and diagnosing systemic lupus erythematosus Active 15-Mar-2013 00000000000
JP-2016516996-A Methods for treating and diagnosing systemic lupus erythematosus Granted 15-Mar-2013 00000000000
EP-2972365-A1 Methods for treating and diagnosing systemic lupus erythematosus Granted 15-Mar-2013 00000000000
EP-2972365-B1 Methods for treating and diagnosing systemic lupus erythematosus Active 15-Mar-2013 G01N33/6893
To view Exagen’s complete patent history, request access »

Exagen Executive Team (22)

Name Title Board Seat Contact Info
Fortunato Rocca Chief Executive Officer & Board Member
Kamal Adawi Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Mark Hazeltine Chief Operating Officer, Operations
Anja Kammesheidt Ph.D Chief Scientific Officer
Tom Macpherson Region Sales Director
You’re viewing 5 of 22 executive team members. Get the full list »

Exagen Board Members (18)

Name Representing Role Since
Ana Hooker Exagen Board Member 000 0000
Brian Birk Sun Mountain Capital Chairman & Board Member 000 0000
Bruce Robertson Ph.D H.I.G. BioHealth Partners Board Member 000 0000
Ebetuel Pallares Ph.D Cottonwood Technology Fund Board Member 000 0000
Fortunato Rocca Exagen Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Exagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 08-Oct-2010 0000000000 000 Diagnostic Equipment
To view Exagen’s complete acquisitions history, request access »